HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
